#### A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 1 2 infection and vaccination 3 4 **Running Title:** A scalable COVID-19 serology solution 5 Karen Colwill<sup>1</sup>, Yannick Galipeau<sup>2</sup>, Matthew Stuible<sup>3</sup>, Christian Gervais<sup>3</sup>, Corey Arnold<sup>2</sup>, Bhavisha 6 Rathod<sup>1,4</sup>, Kento T Abe<sup>1,5</sup>, Jenny H Wang<sup>1</sup>, Adrian Pasculescu<sup>1</sup>, Mariam Maltseva<sup>2</sup>, Lynda Rocheleau<sup>2</sup>, 7 Martin Pelchat<sup>2, 6</sup>, Mahya Fazel-Zarandi<sup>1</sup>, Mariam Iskilova<sup>1</sup>, Miriam Barrios-Rodiles<sup>1</sup>, Linda Bennett<sup>1</sup>, 8 Kevin Yau<sup>7</sup>, François Cholette<sup>8,9</sup>, Christine Mesa<sup>8</sup>, Angel X Li<sup>1,10</sup>, Aimee Paterson<sup>1,10</sup>, Michelle A 9 Hladunewich<sup>7</sup>, Pamela J Goodwin<sup>1,11</sup>, Jeffrey L Wrana<sup>1,5</sup>, Steven J Drews<sup>12</sup>, Samira Mubareka<sup>13</sup>, Allison 10 J McGeer<sup>1,10,14</sup>, John Kim<sup>8</sup>, Marc-André Langlois<sup>2,6\*</sup>, Anne-Claude Gingras<sup>1,5\*</sup>, Yves Durocher<sup>3\*</sup> 11 12 <sup>1</sup> Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada 13 14 <sup>2</sup> Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada 15 <sup>3</sup> Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, 16 Montréal, QC, Canada 17 <sup>4</sup> Current Address: Treadwell Therapeutics, Toronto, ON, Canada <sup>5</sup> Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada 18 19 <sup>6</sup>The Centre for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON, Canada 20 <sup>7</sup> Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada 21 <sup>8</sup>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada 22 <sup>9</sup> Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB 23 <sup>10</sup> Department of Microbiology, at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada 24 <sup>11</sup> Department of Medicine, University of Toronto, Toronto, ON, Canada <sup>12</sup> Canadian Blood Services, Microbiology, Donation Policy and Studies, Edmonton, and Department of 25 26 Laboratory Medicine and Pathology, Division of Diagnostic and Applied Microbiology, University of Alberta, 27 Edmonton, AB, Canada <sup>13</sup> Department of Laboratory Medicine and Molecular Diagnostics, Division of Microbiology, Sunnybrook Health 28 29 Sciences Centre; Biological Sciences, Sunnybrook Research Institute; Division of Infectious Diseases, 30 Sunnybrook Health Sciences Centre; and Department of Laboratory Medicine and Pathology, University of 31 Toronto, Toronto, ON, Canada 32 <sup>14</sup> Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada 33 34 \*Correspondence: 35 Marc-André Langlois: langlois@uottawa.ca Anne-Claude Gingras: gingras@lunenfeld.ca 36 37 Yves Durocher: yves.durocher@cnrc-nrc.gc.ca 38 39 Lead contact: Anne-Claude Gingras: gingras@lunenfeld.ca 40

#### 42 Abstract

43

OBJECTIVES: Antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
 has been instrumental in detecting previous exposures and analyzing vaccine-elicited immune
 responses. Here, we describe a scalable solution to detect and quantify SARS-CoV-2 antibodies,
 discriminate between natural infection- and vaccination-induced responses, and assess antibody mediated inhibition of the spike-angiotensin converting enzyme 2 (ACE2) interaction.

49

50 METHODS: We developed methods and reagents to detect SARS-CoV-2 antibodies by enzyme-linked 51 immunosorbent assay (ELISA). The main assays focus on the parallel detection of immunoglobulin 52 (Ig)Gs against the spike trimer, its receptor binding domain (RBD), and nucleocapsid (N). We 53 automated a surrogate neutralization (sn)ELISA that measures inhibition of ACE2-spike or -RBD 54 interactions by antibodies. The assays were calibrated to a World Health Organization reference 55 standard.

56

57 RESULTS: Our single-point IgG-based ELISAs accurately distinguished non-infected and infected 58 individuals. For seroprevalence assessment (in a non-vaccinated cohort), classifying a sample as 59 positive if antibodies were detected for  $\ge 2$  of the 3 antigens provided the highest specificity. In 60 vaccinated cohorts, increases in anti-spike and -RBD (but not -N) antibodies are observed. We present 61 detailed protocols for serum/plasma or dried blood spots analysis performed manually and on 62 automated platforms. The snELISA can be performed automatically at single points, increasing its 63 scalability.

64

65 CONCLUSIONS: Measuring antibodies to three viral antigens and identify neutralizing antibodies 66 capable of disrupting spike-ACE2 interactions in high-throughput enables large-scale analyses of 67 humoral immune responses to SARS-CoV-2 infection and vaccination. The reagents are available to 68 enable scaling up of standardized serological assays, permitting inter-laboratory data comparison and 69 aggregation.

70

Keywords: SARS-CoV-2, antibody detection, antibody neutralization, assay development and
 standardization, high-throughput screening

#### 74 INTRODUCTION

75

76 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has already induced 77 four major waves of infection in Canada, resulting in > 3.2M confirmed infections and > 36K deaths (as of February 25<sup>th</sup>, 2022<sup>1</sup>). Overall seroprevalence estimates from natural infection during the pre-78 Omicron waves were relatively low compared to other countries <sup>2, 3</sup>, and protecting the population 79 from coronavirus disease of 2019 (COVID-19) has therefore heavily relied on vaccination. Fortunately, 80 81 the dramatic acceleration of vaccination in Canada over the past 8 months has decreased symptomatic infections, severe disease, and deaths <sup>4</sup>; as of February 18<sup>th</sup>, 2022, 84% of the 82 83 population 5 years and older were fully vaccinated  $^{5}$ .

84

However, several important questions remain regarding both infection- and vaccination-induced humoral immunity, including the duration and decay of the immune response, the generation of functional neutralizing antibodies, and the overall differences in humoral responses across groups of individuals with different co-morbidities or following vaccination with different brands and regimens. This information can help guide and prioritize public health programs, such as vaccine booster schedules <sup>6</sup>.

91

92 Plate-based enzyme-linked immunosorbent assays (ELISAs) are widely used scalable methods to 93 quantitatively assess antibody responses to pathogens, including SARS-CoV-2. Microwells are coated 94 with recombinant SARS-CoV-2 protein antigens, and biofluid samples (e.g. serum, plasma, dried blood 95 spot (DBS) eluate, or saliva) are added (Figure 1a). If antibodies that recognize the antigen are 96 present, they are detected with a secondary antibody, typically linked to an enzyme (such as 97 horseradish peroxidase (HRP)) that elicits a measurable change upon addition of a colorimetric or 98 chemiluminescent substrate.

99

100 Because of their potent immunogenicity, antigens derived from the SARS-CoV-2 spike and 101 nucleocapsid (N) proteins have been most frequently used in serological assays, including those 102 developed by commercial vendors. Full proteins, protein segments, and even peptides have been 103 used in these assays which, combined with their different formats and readouts, yield distinct 104 sensitivity and specificity profiles. This can lead to confusion in interpreting results. For example, 105 conclusions about the persistence of antibodies to the nucleocapsid (N) protein differ depending on 106 the platform used, and commercial vendors often do not disclose the exact amino acid sequence of 107 their antigens <sup>7</sup>.

108

109 We have previously used ELISAs to show that immunoglobulin (Ig)G (but not IgM or IgA) against SARS-CoV-2 spike, RBD, and N can persist for at least 3–4 months in the serum and saliva of individuals with 110 COVID-19<sup>8</sup>, an observation now corroborated and extended by several other studies describing the 111 persistence of circulating IgGs up to 13 months (although with gradual declines; e.g. <sup>9-12</sup>). We also 112 showed that the production of neutralizing antibodies capable of preventing interactions between 113 spike (or its RBD) and its target angiotensin converting enzyme 2 (ACE2) could be monitored using a 114 plate-based surrogate neutralization (sn)ELISA <sup>13</sup>. We demonstrated good correlations between this 115 116 assay and both spike-pseudotyped lentiviral and authentic SARS-CoV-2 plague neutralization assays, 117 suggesting that this could provide a scalable and suitable alternative to costly and labor-intensive 118 classical antibody neutralization assessment.

120 While laboratory-based ELISAs like ours have been developed around the world, the various sources of antigens and antibodies used by different groups (in addition to batch-to-batch variation within 121 groups) impede national and international comparisons of seroprevalence and vaccine effectiveness. 122 This is further challenged by the lack of agreed-upon reference standards, with the exception of pools 123 124 of convalescent plasma distributed through the World Health Organization (WHO) to calibrate assays to standardized units <sup>14</sup>. Furthermore, assay performance variability over time remains incompletely 125 examined. To address this, we have developed a reproducible and scalable SARS-CoV-2 serology 126 127 solution using standardized protein reagents and protocols (Figure 1) and independent automated 128 platforms in 2 Canadian laboratories in Toronto and Ottawa. This system has now been used to profile 129 > 150K unique samples, demonstrating its scalability and robustness. Importantly, these reagents and 130 protocols are available to the research community to enable implementation of these assays across 131 laboratories.

- 132
- 133

## 134 Results

135

## 136 **Reagent production**

137 To facilitate comparison of SARS-CoV-2 serology results across Canada, we sought to develop and 138 validate a scalable ELISA-based assay that leverages the mammalian protein expression expertise of 139 the National Research Council of Canada (NRC) Human Health Therapeutics Research Centre. We 140 optimized the production and purification of SARS-CoV-2 proteins (spike trimer, spike RBD, and N 141 from the original Wuhan-Hu-1 strain) to generate large-scale high-purity batches of antigens (Figure 142 1b, Supplementary figures 1 and 2, Supplementary table 1). These were fused with purification tags ((His)<sub>6</sub> and FLAG, with or without a Twin Strep-tag) and expressed in Chinese Hamster Ovary (CHO) 143 cells either as stably transfected pools (spike) or through transient transfection (RBD, N)<sup>8, 15</sup>. Antigens 144 145 were purified by Immobilized Metal Affinity Chromatography (IMAC), with one or two additional purification steps performed for RBD and N (StrepTrap XT columns and/or preparative size exclusion 146 147 chromatography, SEC). The spike and RBD proteins were highly pure when analyzed by SDS-PAGE 148 (Figure 1b). By analytical SEC, spike eluted as a major (>95% integrated area) symmetrical peak of 490 149 kDa (consistent with its trimeric structure) with < 3% hexamers/aggregates, and both versions of RBD 150 (encoding amino acids 319–541 and 331–521, respectively) eluted as single peaks with >95% 151 integrated area. For purified N, some truncated forms were visible by SDS-PAGE/Coomassie staining; 152 however, by SEC, it eluted as a major (>99% integrated area) peak with no apparent larger aggregates. 153 Estimation of molecular weight of N was not possible by multiangle light scattering (MALS), but based on the SEC elution volume, it appears to be ~300 kDa. This is consistent with the formation of 154 tetramers or hexamers by recombinant coronavirus N, as reported by others <sup>16</sup>. For recombinant 155 156 protein production in CHO cells, post-purification yields ranged from 25 mg L<sup>-1</sup> for RBD 331–521 to  $370 \text{ mg L}^{-1}$  for spike (Supplementary table 1). 157

158

The antigen toolbox was supplemented with a detection reagent, namely an anti-human IgG monoclonal antibody (IgG#5) expressed as a HRP fusion in-frame to the heavy chain (HC) C-terminus. This reagent was developed to address an issue common to HRP-based detection reagents from commercial sources, which are usually polyclonal anti-IgG antibodies conjugated to HRP postpurification. These commercial reagents display variability due to the nature of the polyclonal serum used by each supplier, as well as the ratio of conjugated HRP molecules per antibody. IgG#5 was produced by co-transfecting HC and light chain (LC) expression vectors in CHO cells. As shown in

Figure 1, the purified antibody consists of a predominant band at ~110 kDa, which represents the fulllength HC-HRP fusion peptide. A minor band at ~55 kDa is likely a form of the HC lacking HRP (confirmed by western blotting with an anti-mouse-Fc antibody (data not shown)), while the LC presents as a smear between 25 and 37 kDa. Because of this heterogeneity, purified lgG#5-HRP gave a convoluted profile by analytical SEC (Supplementary figure 1).

171

172 To have a common reference that enables intra- and inter-lab comparisons of SARS-CoV-2 antibody responses, we also generated recombinant anti-spike antibodies. Compared to pools of serum or 173 174 plasma from convalescent patients, these offer the advantage of being renewable, scalable, and defined in sequence. Three recombinant single-domain antibodies (VHHs) were selected: VHH72 is a 175 SARS-CoV and SARS-CoV-2 cross-reactive antibody described in Wrapp et al. <sup>17</sup>, and NRCoV2-04 and -176 20 are SARS-CoV-2 spike-binding VHHs developed in-house at the NRC. All antibodies were produced 177 178 in CHO cells and purified on a MabSelect SuRe column. VHH sequences were fused at the C-terminus 179 to Fc1X7 (an antibody-dependent cellular cytotoxicity (ADCC)-attenuated variant of human Fc) to 180 produce dimeric proteins upon secretion from CHO cells. VHH72-Fc eluted as a single symmetrical 181 peak of 102 kDa with < 2% aggregates, NRCoV2-04-Fc eluted with a major peak of 67% integrated 182 area and a peak of 90 kDa, and NRCoV2-20-Fc as a single peak of 100 kDa with < 2% aggregates 183 (Supplementary figures 1 and 2; Supplementary Table 1). The toolbox was further supplemented with a biotinylated ACE2 protein (used for snELISA), which was purified on both IMAC and Strep-Tactin XT 184 185 Superflow columns and elutes from SEC as a single peak of 90 kDa (Supplementary figure 1).

186

187 While the goal is ultimately to have a fully NRC-sourced protein toolbox, the current set of reagents is 188 complemented by a commercial anti-N antibody to quantify the anti-N response (see Methods). As 189 described below, the assays can also be repurposed for IgA/M monitoring with commercial secondary 190 antibodies and matching reference antibodies for calibration.

191

## 192 Direct detection ELISA

We previously developed ELISAs in 96-well colorimetric or 384-well chemiluminescent formats to 193 assess the persistence of antibody responses<sup>8</sup>. This first version relied on small-batch research-grade 194 195 or commercial reagents that are not readily scalable for nationwide surveillance studies. Here, we 196 have first benchmarked the NRC reagents described above, and defined the optimal antigen and 197 secondary antibody amounts in a 384-well automated format (see Methods). The NRC protein toolkit 198 was independently optimized on automated platforms in Toronto (a Thermo Fisher Scientific F7 platform) and Ottawa (a Hamilton system), leading to minor variations in the optimal amounts of 199 200 antigens and detection reagents, in part due to differences in the detectors on each system 201 (Supplementary table 2). While the platforms can be used to generate full titration curves from serum 202 samples, single-point measurements more readily enable scaling up to thousands of samples and 203 have been used in most large-scale studies to date.

204

205 <u>Toronto platform</u>: The optimal dilution for single-point ELISAs was established using a 10-point four-206 fold titration series starting with 0.25  $\mu$ L positive control serum per well (a 1:40 dilution, which is the 207 amount used previously <sup>8</sup>; Supplementary figure 3). A prozone (hook) effect was noted at the 1:40 208 dilution for samples with higher antibody levels, suggesting that a lower concentration was desirable. 209 We performed receiver operating characteristic (ROC) analysis on a set of 300 negative pre-COVID19 210 samples (collected prior to November 2019) and 211 PCR-confirmed convalescent patients (>14 d 211 post-symptom onset) at three different concentrations (Supplementary figure 4), optimizing for an

212 amount of serum that would work with all three antigens. The 0.0625 μL per well serum condition 213 was selected for single-point ELISA based on a reduced hook effect on spike (compared to the highest amount) and better specificity and sensitivity characteristics on its RBD (compared to the lowest 214 215 amount). A final ROC analysis combining data from a second replicate at 0.0625 µL per well at a false 216 positive rate of < 1% revealed sensitivities of 94%, 92%, and 81% for spike trimer, RBD, and N 217 respectively (Table 1, Supplementary figure 4b). Importantly, replicates from experiments conducted 218 8 weeks apart were highly correlated ( $\rho > 0.87$  for all three antigens, Figure 2a), similar to our 219 previous observations<sup>8</sup>, giving us confidence in conducting large-scale cohort studies.

220

221 Ottawa platform: Early optimizations of the serological assay to identify the serum dilution within a 222 linear range with the lowest non-specific reactivity to the negative serum were performed using the 223 manual colorimetric ELISA (Supplementary figure 5). The colorimetric assay was used to test the 224 performance of the HRP-conjugated antibodies, including six different anti-human IgG conjugate 225 antibodies provided by the NRC (Supplementary figure 6a) with different characteristics and enzyme 226 conjugation strategies (e.g. HRP fusion vs conjugation). While all candidates offered good detection, 227 lgG#5—a direct HRP fusion—was selected for further assays, based on its superior quantitative 228 capacity and extremely low non-specific reactivity within a standard reaction time (Supplementary 229 figure 6b). This reagent was also compared to commercial polyclonal and monoclonal secondary 230 antibodies for the detection of anti-spike, -RBD, and -N lgG in DBS samples (see below and 231 Supplementary figure 7c). While all antibodies correctly identified negative and positive DBS samples, 232 IgG-#5-HRP offered the greatest distinction between the negative and positive distributions. To 233 maintain a high level of specificity, the secondary antibody concentration and the nature of substrate 234 were modified between the manual and automated ELISAs (see Supplementary table 2 for the final 235 concentrations).

236

## 237 Setting positivity thresholds in seroprevalence studies

238 One concern with establishing thresholds based on a single sample set is that over time and with 239 variations in sample type (venipuncture vs. capillary blood collection, different collection tubes and 240 handling conditions, etc.), the background of the assay may change, affecting the threshold for 241 reporting positives. In Toronto, we monitored the negative controls (blanks, pre-COVID-19 negative 242 sera, commercially purified  $\lg G$ , n = 1,320 for spike and 1,248 for N and RBD) used in 23 experiments 243 conducted over 4 months. We calculated a threshold of 3 SDs from the mean of the log distribution of 244 these controls and compared it to the thresholds established by ROC analysis (Figure 2b). The 245 thresholds were very similar for N and spike, but the 3 SD range was more stringent for the RBD, 246 decreasing the likelihood of false positive calls. We therefore adopted a threshold of 3 SDs from the 247 mean of these controls for each antigen and recalculated our performance characteristics (Table 1). 248 At this threshold, the specificity for RBD increases to 100% with a slight decrease in sensitivity to 89%, 249 spike retained the same sensitivity and specificity (99% and 94%, respectively), whereas N's sensitivity 250 decreased from 81% to 79% with 99% specificity. The same strategy was applied to IgM and IgA to 251 define stringent thresholds (Supplementary figure 8, Supplementary table 4).

252

Even with these conservative thresholds, an unacceptable number of false calls may be made in low seroprevalence situations (as in Canada, particularly during the first waves of infection). This is shown by the negative samples (red dots in Figure 2a) that passed the thresholds in individual assays. Importantly, these pre-COVID negatives were only ever positive in one test, in contrast to true positives, which tended to pass the positivity thresholds of  $\geq$  2 tests, consistent with the high

correlation between the assays ( $\rho > 0.84$  for all three combinations, with the highest correlation between spike and its RBD; Figure 2c). Our final determination of sample positivity in seroprevalence settings therefore requires that it exceeds the thresholds of at least 2 out of 3 antigens. As can be seen in Figure 2C, this strategy eliminates the false positive calls for the individual antigens (red dots) while retaining similar sensitivity (combined specificity of 100% and sensitivity of 91%).

263

## 264 Harmonization between platforms and testing the WHO standards

To compare our ELISA-based assays with others, we tested them using WHO international reference 265 panel 20/268, comprised of five samples (Negative, Low, Mid, High, and Low S/High N; Figure 3, 266 Supplementary figure 9) and expressed the results in BAU mL<sup>-1</sup> by comparing signals to the WHO 267 268 International Standard (20/136). For this, we used single-point measurements from dilutions that 269 were within the linear range of the International Standard curve (Toronto) or the median of three 270 dilutions (Ottawa). For all five samples, the median results from both labs were highly correlated ( $\rho =$ 271 1 for spike and N, 0.9 for RBD) and were between 0.5–2 fold of the geometric mean (red line with half arrows) reported in a multi-lab comparison by WHO<sup>14</sup>. Importantly, by applying a conversion formula 272 to our relative ratios for expression in BAU mL<sup>-1</sup> (Figure 3d, Supplementary Table 3), our results can be 273 readily compared to other national or international efforts. Using this formula, plasma or serum 274 seropositivity thresholds for IgG are 34, 31, and 11 BAU mL<sup>-1</sup> for nucleocapsid, RBD, and spike 275 respectively (Toronto). When samples are diluted 1:2560, the assays can detect values up to 5344, 276 277 4454 and 1500 BAU mL<sup>-1</sup> for N, RBD, and spike respectively.

278

## DBS testing

280 For serosurveillance, it is important to capture broad swaths of the Canadian population, and at-home sample collection is ideal for this, especially during times of lockdown or restricted movement. DBSs 281 282 are easier to collect, more stable at room temperature, and considered non-hazardous when dried <sup>18,</sup> 283 <sup>19</sup>. We optimized the elution concentrations for both the colorimetric and automated assays (see 284 Methods), and then compared the results of DBS samples and matching plasma samples using 285 reference samples created by the National Microbiology Laboratory (NML; panel 1, with a total of 26 286 different DBSs and matching plasma samples; Supplementary figure 10a). Using NML panel 3, we also 287 found a high correlation in signal between different punch sizes at a constant ratio of punch area to 288 elution volume (Supplementary figure 10b).

289

290 However, despite this high correlation between the two sample types, the higher relative ratios of 291 DBS samples compared to plasma or serum samples shifted the positive and negative density 292 distributions, making direct application of the plasma/serum thresholds inappropriate for scoring 293 seropositivity using DBSs (Supplementary figure 10c). ROC analysis was therefore performed in 294 Toronto and in Ottawa on panel 4, also supplied by the NML (Tables 2 and 3, Supplementary figures 295 11 and 12), yielding sensitivities of 98% for spike and its RBD and 92% for N at a 1% false positive rate 296 threshold in Toronto. By requiring 2 out of 3 calls to be positive, the specificity increased to 100% and 297 the sensitivity was 98%. In Ottawa, at a 3% FDR, the assays achieved 100% sensitivity for each antigen 298 with false positive rates of 2% for spike, 1% for its RBD, and 6% for N. When requiring 2 out of 3 calls 299 to be positive, specificity and sensitivity were both 98%. In the final protocol, we opted to use two 3 300 mm (3.2 mm in Ottawa) punches, as this enables more flexibility and reproducibility when collections 301 are not ideal (which would be typical of self-collection). The minimal sample requirement means the 302 analysis can still be performed even when full DBSs are not provided.

#### 304 snELISA

305 We previously reported an ELISA-based test that functions as a surrogate to more complex 306 neutralization assays employing live viruses, at least with regards to assessing antibodies that prevent the interaction of spike with the ACE2 receptor <sup>13</sup>. In this snELISA, a sample is added to a plate coated 307 308 with RBD or spike antigens (Figure 1a). Instead of a secondary antibody, biotinylated ACE2 is added 309 followed by streptavidin-HRP. If antibodies from the sample recognize the antigen, they will block 310 biotinylated ACE2 from binding, leading to decreased signal when HRP substrate is added. The 311 biotinylated ACE2 was first tested in a manual colorimetric assay using recombinant antibody and 312 known negative and positive samples (Supplementary Figure 13). Both the full-length spike trimer and 313 the RBD domain (319–541 construct) were comparable to prior reagents produced at smaller scale. 314 The assay was then transferred to an automated 384-well chemiluminescent format. Using a panel of 315 samples from the Canadian Blood Services and from two donors after one or two doses of the 316 BNT162b2 (aka Comirnaty; Pfizer-BioNTech) mRNA vaccine, the dose response curves between spike 317 and its RBD were significantly correlated ( $\rho = 0.90$ ; Figure 4A, Supplementary figure 13).

318

319 The snELISA was also implemented on the Ottawa automated platform. Titration of the coating 320 antigen, streptavidin-HRP polymer, and luminescent substrate were performed with varying amounts 321 of biotinylated ACE2 to establish the concentrations with optimal sensitivity, appropriate dynamic 322 range, and a minimized hook effect at high ACE2 concentrations (Supplementary figure 14). The final 323 concentration of ACE2 per well was established at 6.5 ng, using 100 ng/well of coated antigen and the 324 substrate diluted 1:2. Using these conditions, we were able to generate consistent neutralization 325 efficiency measurements with serum and plasma (Figure 4B, Supplementary figure 15), enabling us to 326 calculate effective concentration for 50% inhibition (EC50) values for convalescent sera and in sera from doubly vaccinated individuals. We also tested a panel of 121 positive and six negative samples 327 from the Stop the Spread Ottawa study as single point measurements at a 1:5 dilution using spike as 328 329 the antigen (Figure 4C). Convalescent samples ranged from 0–100% inhibition, with a median value of 330 70%. The six negative samples ranged from 0-32% inhibition with a median of 26%, consistent with 331 our previous observation that pre-pandemic samples can achieve partial inhibition of the spike-ACE2 interaction due to cross-reactivity of antibodies targeting seasonal coronaviruses <sup>20</sup>. For DBS samples, 332 333 four 3 mm punches eluted in 100  $\mu$ L of PBS from a double-vaccinated individual showed measurable 334 neutralization activity (Supplementary figure 15); however, we were unable to measure neutralization 335 in DBS samples from convalescent or singly vaccinated individuals (in contrast to serum). Therefore, 336 while it is possible to detect neutralization activity from DBSs, this is limited to samples with high 337 neutralizing activity. Additionally, DBS samples might not be ideal for quantitative neutralization 338 measurements, as sample quality, paper saturation, and disc punching consistency can interfere with 339 the reproducibility and reliability of the results.

340

341 The final development performed with the snELISA was to correlate binding inhibition to international units (IUs) of the WHO International Standard (Figure 4D). By titrating the standard, we established 342 343 the correlation between binding inhibition and IUs within the linear range of the curve, with 0.251 IUs 344 being required to inhibit ACE2-spike interaction by 50% (EC50). We then tested the WHO reference 345 panel 20/268 by snELISA using spike (Ottawa) or RBD (Toronto) as antigens (Figure 3E). For the low, 346 mid and high samples, results from Toronto and Ottawa were between 0.5-2 fold of the geometric mean (red line with half arrows) reported in a multi-lab comparison by the WHO<sup>14</sup>. For the low S, 347 348 high N sample, there was no inhibition of ACE2 binding in the snELISA using RBD as the antigen, in 349 contrast to the snELISA using full-length spike which detected inhibition levels similar to the WHO

350 study. Given the numerous different protocols and strategies that are being used to measure 351 neutralizing antibodies such as spike-pseudotyped lentiviral assays, plaque reduction neutralization 352 tests (PRNT) and the snELISA, transforming the data to IUs will enable more robust cross-laboratory 353 and cross-assay correlations to be performed.

354

## 355 Visualization of the results of seroprevalence and vaccination studies

356 As defined above, the assays optimally use the IgG responses to three antigens (spike, RBD, N) to report seropositivity resulting from SARS-CoV-2 infection. To illustrate how vaccination cohorts differ 357 358 from infected cohorts, we re-plotted a subset of the data from our training set (positives and negatives) as pairwise comparisons of spike and N on scatterplots, with the color intensity mapping to 359 360 that of RBD (Figure 5A). We also replotted data from a cohort of vaccinated patients on dialysis<sup>21</sup> 361 prior to vaccination and 6 weeks afterward (Figure 5B). As expected, the infected cohort contained 362 samples largely positive for all three antigens tested, while the vaccinated cohort largely consisted of samples positive for spike and its RBD, but negative for N, which is not targeted by vaccines used in 363 364 Canada. This type of visualization helps define individuals with evidence of infection from those with 365 antibodies resulting from vaccination.

366

## 367 **Discussion**

368

369 In this paper, we describe a toolkit and protocols for both SARS-CoV-2 serosurveillance and 370 vaccination response profiling that we applied to populations studies in Canada. We have validated 371 these reagents, produced and made available by the NRC, in two separate laboratories. The results can be expressed as relative ratios or can be converted into international units (BAU mL<sup>-1</sup> for antibody 372 detection, IU mL<sup>-1</sup> for antibody neutralization) to facilitate comparisons between labs and with studies 373 proposing correlates of protections based on these units <sup>22</sup>. We validated antibody detection and 374 surrogate neutralization assays in 96-well format (manual colorimetric assays) and on two different 375 376 384-well automated chemiluminescent platforms, enabling these reagents to be used at small-scale in 377 laboratories with basic equipment and in dedicated high-throughput facilities equipped with different 378 automation equipment.

379

All vaccines approved for use in Canada (also in USA and Europe) use spike as the immunogen <sup>23-25</sup>. For those who have been vaccinated, responses to spike (and its RBD) are expected, whereas a response to N is only expected after infection. Thus, it is of value to focus on these two orthogonal readouts when detecting and characterizing immune responses <sup>26</sup>. Adding the spike RBD as a third antigen increases specificity [of the three antigens, it is the least conserved in coronaviruses <sup>27-29</sup>] and provides insight into possible protection, as it is also the antigen most correlated with neutralization potential <sup>13, 30, 31</sup>.

387

By definition, single point assays must make compromises in defining antigen/antibody/detection antibody amounts to ensure that a large fraction of measurements are within the linear range of quantification. Here, we have optimized the concentrations of the serum/plasma/DBS eluates used to capture the most positives (i.e. convalescent individuals) possible without inducing a hook effect. Still, in samples with very high antibody levels (including those from healthy individuals following two doses of vaccine), the measured antibody levels will saturate the assay, thereby preventing their accurate measurement. When the relative amounts of antibodies detected across samples is

important to measure, expanded dilutions should be performed (note that this drastically decreases
 assay throughput and increases costs). As a compromise, in vaccinated cohorts, we routinely perform
 two-point dilution (16-fold difference) assays that expand the range of concentrations that can be
 measured in the linear range of quantification, from 1 BAU mL<sup>-1</sup> to 1500 BAU mL<sup>-1</sup> for spike, and from
 BAU mL<sup>-1</sup> to 4454 BAU mL<sup>-1</sup> for RBD.

400

401 We also optimized our seropositivity thresholds to limit false positives, both by providing a stringent 402 definition of positivity in each assay, and by requiring that this positivity threshold be met in two 403 separate assays to establish overall positivity in seroprevalence studies. While we felt this was 404 essential to avoid inflating the positive calls in low prevalence settings, it may affect the overall 405 sensitivity of the assays, especially following recent infection/vaccination (where seroconversion for anti-spike often precedes that of RBD and N<sup>8</sup>) or as antibody levels decay. Other limitations stem 406 from the selection of antigens, as those used in these assays are from the original Wuhan-Hu-1 strain, 407 408 and it is possible that decreased sensitivity occurs when testing patients infected with variants, 409 especially Omicron which has 30 amino acid substitutions (15 within the RBD), three small deletions and one small insertion in the spike coding sequence <sup>32</sup> [though our initial results with non-vaccinated 410 Omicron-infected convalescents indicate detection of anti-RBD lgG on this assay; optimization of 411 412 assays based on Omicron sequences is ongoing]. Lastly, as assays using N generally have poorer 413 specificity and sensitivity (at our defined thresholds) than RBD- and spike-based assays, they may not 414 be ideal as a stand-alone method to define vaccine breakthrough infections, unless serial blood 415 samples are available (in which case an increase in anti-N levels would indicate that an infection has 416 occurred). Further assay development will include additional viral antigens not contained in the 417 vaccines to increase the detection sensitivity for antibodies produced in breakthrough infections. The 418 control over reagent production and quality, and the flexibility of the ELISA platforms to 419 accommodate new antigens also provide a rapid route to testing immune responses to variants. All reagents and protocols are publicly available to enable the rapid deployment of these assays. 420

421

422 The validated automated ELISA assays described here are currently being used in multiple Canadian 423 studies (with >150,000 unique samples profiled to date). These include large serosurveys that monitor 424 the global (and regional) humoral response (from both infection and vaccination) in the Canadian 425 population, including the Canadian COVID-19 Antibody and Health Survey from Statistics Canada<sup>2</sup>, seroprevalence studies with Canadian Blood Services <sup>33, 34</sup>, the Action to Beat Coronavirus study <sup>35</sup>, 426 and the Canadian Partnership for Tomorrow's Health study <sup>36</sup>. Additionally, these assays are used in > 427 30 studies focused on infection and/or vaccine responses across different cohorts, e.g. in persons 428 predicted to have a weaker immune response (based, for example on age <sup>37</sup> or health conditions <sup>38</sup>), 429 430 or who are likely to be exposed to infection from the workplace. The results of the assays have critically helped informed public health decisions. Based on, e.g. a weak response to vaccine in older 431 adults or patients on dialysis <sup>21, 39</sup>, or the decline in antibody levels post-dose 2 in residents of long-432 term care homes <sup>40, 41</sup>, prioritizations were made for second doses, vaccine type was recommended, 433 or additional doses were accelerated in the populations studied. Combined with other studies 434 coordinated by the COVID-19 Immunity Task Force (CITF)<sup>42</sup>, our serology studies help guide Canada's 435 response to the COVID-19 pandemic. 436

- 437
- 438 Methods
- 439
- 440 **Protein production**

441 Spike trimer: The SARS-CoV-2 spike ectodomain construct (SmT1) from the Wuhan-Hu-1 strain with S1/S2 furin site mutations. K986P/V987P prefusion-stabilizing mutations, and human resistin as a 442 trimerization partner <sup>15</sup> was produced using stably transfected Chinese Hamster Ovary (CHO) pools 443 (CHO<sup>BRI/2353™</sup> cells) and purified as described<sup>8</sup>. To prepare reference material alignots for distribution 444 by the National Research Council of Canada (NRC) Metrology Research Centre, the bulk purified 445 446 protein was formulated in PBS supplemented with 10 mM HEPES sodium salt. After aliquoting and 447 one freeze-thaw cycle, protein integrity and purity were assessed by sodium dodecyl sulfate-448 polyacrylamide gel electrophoresis (SDS-PAGE; Figure 1B) and analytical size-exclusion ultra-high 449 performance liquid chromatography (SEC-UPLC; Supplementary figure 1, Supplementary table 1). SEC-450 UPLC was run on an Acquity H-Class Bio UPLC system (Wyatt Technology, Santa Barbara, CA, USA) in 451 phosphate buffered saline (PBS) + 0.02% Tween-20 on a 4.6 × 300 mm Acquity BEH450 column (2.5 452 µm bead size; Waters Limited, Mississauga, ON, Canada) coupled to a miniDAWN Multi-Angle Light 453 Scattering (MALS) detector and Optilab T-rEX refractometer (Wyatt).

454

455 Nucleocapsid: N cDNA (corresponding to amino acids 1-419 of YP 009724397, Wuhan-Hu-1 strain) was synthesized by GenScript (Piscataway, NJ, USA; using Cricetulus griseus codon bias) with a C-456 terminal FLAG-Twin-Strep-tag-(His)<sub>6</sub> tag and cloned into the pTT5<sup>®</sup> expression plasmid (NRC) to create 457 NCAP <sup>43</sup>. Expression by transient transfection of  $CHO^{BRI/55E1^{TM}}$  cells was performed using a previously 458 described high cell density method <sup>15</sup>. Since a significant proportion of N was released from 459 transfected cells despite high viability, it was purified from the culture supernatant. Following 460 461 centrifugation and filtration, supernatant harvested 7 d post-transfection was purified by immobilized 462 metal affinity chromatography (IMAC) on a Ni Sepharose Excel column (Cytiva, Vancouver, BC, 463 Canada). The column was washed with 50 mM sodium phosphate buffer (pH 7.0) containing 25 mM 464 imidazole and 300 mM NaCl, and N was eluted with 50 mM sodium phosphate buffer (pH 7.5) containing 300 mM imidazole and 300 mM NaCl. N was further purified by affinity chromatography 465 on a StrepTrap XT Chromatography Column (Cytiva) equilibrated in Buffer W (100 mM Tris pH 8.0, 150 466 467 mM NaCl). The column was washed with Buffer W and bound protein was eluted with Elution Buffer 468 (Buffer W supplemented with 50 mM biotin and 1 mM ethylenediaminetetraacetic acid (EDTA)). 469 Purified N was buffer exchanged into Dulbecco's PBS (PBS) using a CentriPure P100 Gel Filtration 470 Column (Apex Scientific, Maynooth, Ireland), sterile-filtered through a 0.2 µm membrane, and stored 471 at -80°C. For preparation of reference material aliguots (NCAP-1) for distribution by National Research 472 Council of Canada (NRC) Metrology, the bulk purified protein was processed through an additional 473 buffer exchange in 50 mM Tris-HCl pH 8.0 supplemented with 150 mM sodium chloride. N integrity 474 and purity was analyzed by SDS-PAGE and analytical SEC-HPLC, which was run in PBS supplemented 475 with 200 mM arginine on a  $5 \times 150$  mm Superdex 200 HR column (Cvtiva).

476

477 RBD: Amino acids 331–521 of the SARS-CoV-2 spike protein (YP 009724390.1, Wuhan-Hu-1 strain) 478 were cloned into the pTT5<sup>®</sup> vector using EcoRI and BamHI. The construct encodes an N-terminal 479 human interleukin 10 signal peptide (MHSSALLCCLVLLTGVRA) followed by a Twin-Strep-tag II-(His)<sub>6</sub>-FLAG tag fused to the RBD N-terminus. The construct was expressed by transient gene expression in 480 CHO<sup>BRI/55E1™</sup> cells as described above <sup>15</sup>. Clarified culture supernatant harvested 8 d post-transfection 481 482 was purified by IMAC on Ni Sepharose Excel columns as above. The IMAC eluate was buffer-483 exchanged using NAP-25 columns (Cytiva) into PBS before a second affinity purification step using 484 Strep-Tactin XT Superflow (IBA Lifesciences, Göttingen, Germany), following the manufacturer's instructions. The pooled eluate (de-salted into PBS and concentrated) was applied to a Superdex-75 485 gel filtration column (Cytiva). SEC fractions containing RBD with low levels of high-molecular-weight 486

487 contaminants were pooled. The second RBD construct ( $RBD^{319-541}$ ) consists of amino acids 319–541 488 with a C-terminal (His)<sub>6</sub>-FLAG tag. The protein was expressed and purified as described for  $RBD^{331-521}$ , 489 except the Strep-Tactin XT purification step was omitted.

490

RBD and N antigens were compared against previously validated antigens produced by the Rini and
 Sicheri laboratories, respectively, and described in <sup>8, 13</sup>.

493

494 Recombinant antibody production: VHH and mAb sequences were synthesized by GenScript using C. 495 griseus codon bias and cloned into the pTT5<sup>®</sup> plasmid. The llama single domain antibody (VHH) VHH72 was described previously (PDB entry 6WAQ 1)<sup>17</sup>. Additional VHHs (NRCoV2-04 and NRCoV2-496 497 20) were isolated in-house from llamas immunized with recombinant SARS-CoV-2 trimeric spike 498 ectodomain SmT1 (Supplementary figure 2). VHH sequences were fused to an antibody-dependent 499 cell-mediated cytotoxicity (ADCC)-attenuated human IgG1 Fc domain (hFc1X7, from patent US 2019 500 352 383A1) to generate VHH72-Fc, NRCoV2-04-Fc and NRCoV2-20-Fc. The anti-human-lgG 501 monoclonal antibodies (mAbs) IgG#5 and IgG#6 were derived from mice immunized with human IgG; 502 heavy chain (HC) and light chain (LC) variable domain sequences (VH and VL) were fused to mouse 503 IgG2a and mouse kappa LC constant domain sequences, respectively, to express full-length mAbs. The 504 HC was fused in-frame at its C-terminus with ferric HRP (PDB: 1W4W A) to create IgG#5-HRP and 505 IgG#6-HRP. These mAbs were also tested as HRP conjugates (rather than HRP fusions) as described in 506 Supplementary figure 6. For protein production, VHH or mAb HC/LC (50:50 w/w) plasmids were transfected into CHO<sup>BRI/55E1™</sup> cells using PEI-Max transfection reagent (Polysciences, Warrington, PA, 507 USA) as described previously <sup>13, 15</sup>. Clarified 0.2 µm-filtered supernatants were loaded on 5 mL HiTrap 508 509 MabSelect SuRe columns (Cytiva) equilibrated in PBS, and the columns were washed with PBS prior to 510 antibody elution with 100 mM citrate buffer, pH 3.6. The eluted antibodies were formulated in PBS by 511 buffer exchange using NAP-25 columns. Purified proteins were quantified based on their absorbance 512 at 280 nm and analyzed by analytical size-exclusion on an Acquity BEH200 column (Waters) by UPLC-513 MALS system (as described above for the spike trimer) or on a 5 × 150 mm Superdex 200 HR column (Cytiva) coupled to a high-performance liquid chromatography (SEC-HPLC) system (Waters). 514

515

516 Biotinylated ACE2 production: The human ACE2 (UniProtKB-Q9BYF1) cDNA was synthesized by GenScript and optimized for expression in CHO cells. The construct encodes a human interleukin 10 517 518 signal peptide (MHSSALLCCLVLLTGVRA) followed by a Twin-Strep-tag II-(His)<sub>6</sub>-FLAG tag on the N-519 terminus of the mature ACE2 receptor ectodomain (amino acids 20–613). A biotin acceptor peptide 520 (BAP) sequence (GLNDIFEAQKIEWHE) was added in-frame at the ACE2 C-terminus. The cDNA was 521 cloned into pTT5<sup>®</sup> using EcoRI and BamHI. The ACE2-BAP cDNA was expressed by transient gene expression in CHO<sup>BRI/55E1<sup>M</sup></sup> cells as described <sup>15</sup> with the addition of 5% (w/w) pTT5<sup>®</sup>-BirA (an 522 *Escherichia coli* biotin ligase) expression plasmid as described previously <sup>44</sup>. Clarified culture 523 524 supernatant harvested 8 d post-transfection was purified by IMAC on Ni Sepharose Excel columns as described for N above. The IMAC eluate was buffer-exchanged using NAP-25 columns into PBS before 525 526 a second affinity purification step using Strep-Tactin XT Superflow. The pooled eluate (buffer-527 exchanged into PBS as above) was stored at -80°C. Biotinylated ACE2 from the NRC was compared against biotinylated ACE2 produced in the Rini lab and previously described in <sup>13</sup>. 528

529

# 530 **Participant recruitment and study approval**

531 All research was performed in accordance with Canada's Tri-Council Policy Statement: Ethical Conduct

532 for Research Involving Humans. External samples and data were transferred via Materia and Datal

533 Transfer Agreements as appropriate. Samples were de-identified prior to transfer to the assay 534 laboratory.

535 For Toronto cohorts: Negative control serum samples were from patients enrolled in cancer studies 536 pre-COVID-19 (prior to November 2019; Mount Sinai Hospital (MSH) Research Ethics Board (REB) 537 studies #01-0138-U and #01-0347-U), which were archived and frozen in the Lunenfeld-Tanenbaum 538 Research Institute (LTRI) Biobank. Convalescent serum samples were obtained from in- and out-539 patients with polymerase chain reaction (PCR)-confirmed COVID-19 by the Toronto Invasive Bacterial 540 Diseases Network in Toronto and the regional municipality of Peel, Ontario (REB studies #20-044 541 Unity Health Network, #02-0118-U/05-0016-C, MSH). Specimen-only Canadian Blood Services (CBS) 542 serum donations were collected from individuals who met one or more of the following criteria: (a) 543 indicated they had a SARS-CoV-2-positive PCR test, (b) a declaration of having been a close contact of 544 a COVID-19 case, (c) a travel history and clinical presentation compatible with COVID-19, and (d) signs 545 and symptoms compatible with COVID-19. ELISAs were conducted at the LTRI with MSH Research Ethics Board (REB) approval (study number: 20-0078-E). Samples from vaccinated individuals were 546 547 obtained from Sunnybrook Health Sciences Centre (REB study #4814, Sunnybrook, #21-0049-E, MSH) 548 and from MSH (REB study #20-0144-A).

549 For Ottawa cohorts: Pre-pandemic serum and plasma samples were collected between April 2015 and 550 December 2019 from diverse sources, including the Eastern Ontario Regional Laboratory Association 551 (EORLA) and the Ottawa Hospital (TOH). Pediatric samples were acquired from the BC Children's 552 Hospital Biobank (BCCHB) in Vancouver, BC, Canada (REB#: H-07-20-6009). Pandemic samples were collected from longitudinal studies of severe and mild hospitalized cases of COVID-19 (REB # H-04-20-553 554 5727 and # H-11-20-6172), and from a surveillance study of at-risk and convalescent individuals called 555 Stop the Spread Ottawa (REB # H-09-20-6135) at the Ottawa Hospital Research Institute and the 556 University of Ottawa.

557

## 558 Sample collection, handling, and viral inactivation

559 <u>Serum and plasma collection:</u> Samples were collected using standard phlebotomy procedures at 560 collection sites or self-collected by individuals after capillary puncture. In Toronto, inactivation of 561 potential infectious viruses in plasma or serum was performed by incubation with Triton X-100 to a 562 final concentration of 1% for 1 h prior to use <sup>8, 45</sup>. Serum and plasma samples collected and processed 563 in Ottawa did not require viral inactivation, as they were handled and tested within the University of 564 Ottawa CL2+ biocontainment facility.

565

DBS preparation: Samples were prepared at the National Microbiology Laboratory of Canada (NML) as 566 in <sup>46</sup>. For panels 1–3, plasma from SARS-CoV-2 antibody-positive COVID-19 convalescent donors (MSH, 567 568 Toronto) and SARS-CoV-2-negative donors (NML, Winnipeg) were used to generate matched plasma 569 and contrived DBS samples. For contrived DBS samples, fresh SARS-CoV-2 antibody-negative blood 570 was centrifuged, the plasma was removed, and the red blood cells were resuspended 1:1 in antibody-571 positive plasma and spotted (5 × 75 µL) onto Whatman 903 Protein Saver Cards (GE Healthcare, 572 Boston, MA, USA), which were dried at room temperature overnight, then stored with desiccant in 573 gas-impermeable bags at -80°C until testing. SARS-CoV-2 antibody-negative blood was spotted 574 directly from EDTA Vacutainer tubes onto DBS cards. For panel 4, both positive and negative blood 575 samples were spotted directly from EDTA tubes. All matched plasma and contrived DBS samples were 576 tested using the anti-SARS-CoV-2 ELISA IgG kit (EUROIMMUN, Lübeck, Germany), according to the 577 manufacturer's instructions, to verify that donors were either positive or negative for SARS-CoV-2 578 antibodies prior to shipping to Toronto and Ottawa.

#### 579

580 DBS handling: Toronto: Samples from DBS cards were punched manually using a 6 mm punch or in a semi-automated manner using a BSD600 Ascent puncher (BSD Robotics, Brisbane, QLD, Australia) 581 582 with the indicated punch size. We first compared 6 mm circle punches from contrived DBSs and matching plasma samples (Supplementary figure 10) by eluting the punches in 250 µL PBST plus 1% 583 Triton X-100 (0.226 mm<sup>2</sup>  $\mu$ L<sup>-1</sup> eluate). After this initial test, to ensure sufficient eluate to test all three 584 antigens from 1 or 2 3-mm punches, we selected a final elution ratio of 0.176 mm<sup>2</sup> µL<sup>-1</sup> elution buffer 585 (i.e. 80  $\mu$ L for 2 × 3 mm punches). Eluted samples were centrifuged at 1,000 × g for 30 s before 586 587 transfer to 96-well plates. Eluates were diluted 1:4 in 1.3% Blocker BLOTTO (Thermo Fisher Scientific, 588 Waltham, MA, USA) to a final concentration of 1% in PBST, unless otherwise specified.

589

590 <u>DBS handling: Ottawa</u>: Samples from DBS cards were punched manually or in a semi-automated 591 manner using a DBS puncher (PerkinElmer, Woodbridge, ON, Canada; 3.2 mm discs) or a BSD600 592 Ascent puncher (BSD Robotics; 3 mm discs) and eluted in 100  $\mu$ L per disc PBS + 1% Triton X-100 for up 593 to 16 h (minimum 4 h) in 96-well U-bottom plates on a shaker at room temperature. Elution 594 optimization data are presented in Supplementary Figure 7. Eluates were centrifuged at 216 × g for 2 595 min and diluted 1:2 in 2% milk + PBST for a final concentration of 1% milk in PBST.

596

#### 597 Colorimetric direct ELISAs: Toronto protocol

598 Manual colorimetric ELISAs were adapted from assays described in <sup>8, 13</sup>. Antigens (spike trimer, RBD 599 331–521, and N) at the indicated amounts (in ng, see Supplementary table 2 for optimized amounts) 600 were diluted in 50 µL PBS and adsorbed onto a 96-well high-binding polystyrene Greiner Bio-One 601 plate (Thermo Fisher Scientific, #655061) overnight at 4°C. Wells were washed three times with 200 602 µL PBST and then blocked with 200 µL 3% w/v milk powder (BioShop Canada Inc., Burlington, ON, Canada, #ALB005.250) in PBST for 1-2 h at room temperature. Samples were diluted as indicated in 603 604 50 μL of 1% w/v (final) milk powder in PBST and added to each plate. A standard curve of recombinant 605 antibody was added to each plate in 50 µL 1% w/v milk powder in PBST at the indicated 606 concentrations. For spike and its RBD, the recombinant antibodies used were VHH72-Fc (NRC; see 607 above), human anti-spike S1 IgG (clone HC2001, GenScript, #A02038), human anti-Spike S1 IgM (clone 608 hlgM2001, GenScript, #A02046), and human anti-spike IgA (clone CR3022, Absolute Antibody, Oxford, 609 United Kingdom, #Ab01680-16.0). For N, the antibodies used were human anti-nucleocapsid IgG 610 (clone HC2003, GenScript, #A02039), anti-nucleoprotein IgM (CR3018 (03-018), Absolute Antibody, 611 #Ab01690 -15.0), and anti-nucleoprotein IgA (CR3018 (03-018), Absolute Antibody, #Ab01690 -16.0). Negative control antibodies purified from human serum (final 1 µg mL<sup>-1</sup>; human lgG, Sigma-Aldrich, 612 Oakville, ON, Canada, #14506; human IgM, Sigma-Aldrich #18260, human IgA, Sigma-Aldrich, #14036) 613 614 and pools of positive and negative sera from 3–4 patients were added to each plate in 50 µL 1% w/v 615 milk powder in PBST for quality control and to enable cross-plate comparisons. Samples were 616 incubated for 2 h at room temperature, and wells were washed three times with 200 µL PBST. Anti-617 human secondary antibodies (recombinant anti-human IgG#5-HRP, goat anti-human IgG Fcy-HRP (Jackson ImmunoResearch Labs, West Grove, PA, USA, #109-035-098), goat anti-human IgM fc5u-HRP 618 619 (Jackson ImmunoResearch Labs, #109-035-129), and goat anti-human IgA  $\alpha$  chain-HRP (Jackson 620 ImmunoResearch Labs, #109-035-127) were added to the plate at the indicated dilutions in 50  $\mu$ L 1% 621 w/v milk powder in PBST and incubated for 1 h at room temperature. Wells were washed three times 622 with 200 µL PBST, then 50 µL of 1-Step Ultra TMB-ELISA Substrate Solution (Thermo Fisher Scientific, 623 #34029) was added for 15 min at room temperature. The reaction was guenched with 50  $\mu$ L Stop 624 Solution for TMB Substrates (Thermo Fisher Scientific, #N600). The plates were read at 450 nm in a

625 Cytation 3 Cell Imaging Multi-Mode Reader (BioTek Instruments Inc., Winooski, VT, USA). Blank values 626 (the mean of the blanks in each 96-well plate) were subtracted from all raw reads prior to data 627 analysis.

628

## 629 Colorimetric direct ELISA: Ottawa protocol

Manual colorimetric ELISAs were modified from the assay described in <sup>47</sup>. High protein-binding 630 Immulon 4 HBX clear 96-well plates (VWR International, Mississauga, ON, Canada, #62402-959, note 631 these plates have also been tested and validated in Toronto) were coated with 50  $\mu$ L of 2  $\mu$ g mL<sup>-1</sup> 632 633 antigen (spike, RBD 319-541, and N diluted in sterile PBS (WISENT Inc, St-Bruno, QC, Canada, #311-634 010-CL)) were incubated at 4°C on a shaker overnight. The next day, coated plates were washed three times with 200 µL of PBST and blocked with 200 µL of 3% w/v skim milk powder in PBST for 1 h at 635 636 room temperature on a shaker at 700 rpm. The blocking buffer was removed, and plates were 637 washed three times with 200 µL PBST. Serum and plasma samples were diluted in 1% w/v skim milk 638 powder in PBST. An isotype-specific standard curve was included on each plate to enable cross-plate 639 comparison: anti-SARS-CoV-2 S CR3022 Human IgG1 (Absolute Antibody, Ab01680-10.0), anti-SARS-640 CoV-2 S CR3022 Human IgA (Absolute Antibody, Ab01680-16.0), or anti-SARS-CoV-2 S CR3022 Human 641 IgM (Absolute Antibody, Ab01680-15.0). Serum/plasma samples, standard curve, positive and 642 negative controls, and blanks (100 µL/well in 1% w/v skim milk in PBST) were added and incubated for 643 2 h at room temperature on a plate shaker at 700 rpm. The plates were washed four times with 200 644  $\mu$ L PBST, HRP-linked secondary antibody diluted in 1% milk in PBST (50  $\mu$ L) was added, and the plate 645 was incubated for 1 h at room temperature on a shaker at 700 rpm. The final isotype-specific 646 secondary antibodies used were anti-human IgG#5-HRP (Supplementary figure 6), anti-human IgA-647 HRP (Jackson ImmunoResearch Labs, 109-035-011), and anti-human IgM-HRP (Jackson 648 ImmunoResearch Labs, 109-035-129). Plates were washed four times with 200 µL PBST and developed using 100 µL of SIGMAFAST OPD Tablets (Sigma-Aldrich, P9187) dissolved in 20 mL Gibco 649 Water for Injection for Cell Culture (Thermo Fisher Scientific, A1287301, final concentration of 0.4 mg 650  $mL^{-1}$  OPD, 0.4 mg  $mL^{-1}$  urea hydrogen peroxide, and 0.05 M phosphate-citrate, pH 5.0). After 10 min 651 of incubation in the dark, the reaction was stopped with 50  $\mu$ L of 3 M HCl and the absorbance was 652 653 measured at 490 nm using a PowerWave XS2 Plate Reader (BioTek Instruments). Wells filled with 654 dilution buffer were used as background controls and their reads were subtracted from serum values. 655 Colorimetric assay optimization data are presented in Supplementary figures 5 and 6.

656

## 657 Chemiluminescent direct ELISA: Toronto protocol and optimization

Automated chemiluminescent ELISAs were adapted from assays first described in <sup>8</sup>, and performed 658 using liquid dispensers (Biomek NXp (Beckman, Indianapolis, IN, USA), Multidrop Combi (Thermo 659 660 Fisher Scientific)) and a washer (405 TS/LS LHC2 (Biotek Instruments)); all wash steps included four 661 washes with 100 µL PBST) on a Thermo Fisher Scientific F7 Robot System at the Network Biology Collaborative Centre (nbcc.lunenfeld.ca). All incubations were performed at room temperature. 662 663 Antigen (spike trimer, RBD 331–521, or N) at the indicated amounts (ng) were diluted in 10 µL PBS and dispensed into the wells of a 384-well LUMITRAC 600 high-binding polystyrene Greiner plate 664 665 (Thermo Fisher Scientific, #781074). The plate was centrifuged at 233  $\times q$  for 1 min to ensure even coating, incubated overnight at 4°C, and washed. Wells were blocked with 80 µL of 5% Blocker 666 BLOTTO for 1 h and then washed. Samples and controls (as in the colorimetric assay) were diluted as 667 668 indicated in a final concentration of 1% Blocker BLOTTO in PBST, and 10 µL was added to each well from 96- or 384-well source plates. Plates were incubated for 2 h, and wells were washed with PBST. 669 Secondary antibodies (as in the colorimetric assay) were diluted as indicated in 1% Blocker BLOTTO in 670

671 PBST and 10  $\mu$ L was added to each well. After incubation for 1–2 h, the wells were washed and 10  $\mu$ L 672 of ELISA Pico Chemiluminescent Substrate (Thermo Fisher Scientific, #37069, diluted 1:4 in ddH<sub>2</sub>0) was 673 dispensed into each well and mixed at 900 rpm for 10 s. After a 5–20-minute incubation, plates were 674 read on an EnVision 2105 Multimode Plate Reader (PerkinElmer) at 100 ms/well using an ultra-675 sensitive luminescence detector.

676

677 Protein reagents from the NRC (described above) were first optimized in the 96-well colorimetric manual assay using recombinant antibodies and serum samples from CBS (Supplementary figure 16). 678 679 The final amount of antigen per well was then scaled down by 3.5–4-fold to migrate to 384-well 680 format for the automated assay. Two concentrations of secondary antibody IgG#5-HRP (0.09 and 0.18 681 µg mL<sup>-1</sup>) were assessed using dilution curves of the VHH72-Fc antibody (to detect spike and its RBD) or 682 an anti-N antibody (to detect N; Supplementary figure 17), and the best concentration (0.18  $\mu$ g mL<sup>-1</sup>) 683 was further tested on a dilution series of 32 serum samples provided by CBS (Supplementary figure 3). 684 We also tested anti-RBD NRCoV2-04-Fc and NRCoV2-20-Fc recombinant calibration antibodies, which 685 were comparable to VHH72-Fc as reference curves (Supplementary figure 17). For IgA and IgM 686 detection, reagents were first tested in the colorimetric assay (Supplementary figure 8). For 687 chemiluminescent assays, 10 μL of goat anti-human IgM-HRP (1:10,000; 0.80 ng/well) or goat anti-688 human IgA-HRP (1:12,000, 0.66 ng/well) were used as secondary antibodies.

689

## 690 Chemiluminescent direct ELISAs: Ottawa protocol and optimization

691 Automated chemiluminescent ELISAs were based upon and optimized from assays first described in 692 <sup>48</sup>, and performed using MicroLab Star robotic liquid handlers (Hamilton, Reno, NV, USA) and a 405 693 TS/LS LHC2 plate washer (Biotek Instruments; all wash steps included four washes with 100 µL PBST) 694 at the University of Ottawa, Faculty of Medicine (Roger Guindon Hall). All incubations were done at 695 room temperature with shaking at 500–700 rpm. Antigens (spike, RBD 319–541, and N) were diluted 696 in PBS and dispensed into the wells of a 384-well high-binding polystyrene Nunc plate (Thermo Fisher 697 Scientific, #460372) at a final amount of 50 ng/well. The plates were centrifuged at  $216 \times g$  for 1 min 698 to ensure even coating, incubated overnight rocking at 4°C, and washed. Wells were blocked with 80 699 µL of 3% w/v skim milk powder dissolved in PBST for 1 h and then washed. Samples and controls were 700 diluted as indicated to a final concentration of 1% w/v skim milk powder in PBST and 10 µL was added 701 to each well from a 96-well source plate. Plates were incubated for 2 h and wells were washed. 702 Secondary antibodies (as in the colorimetric assay) were diluted as indicated in 1% w/v skim milk 703 powder in PBST and 10 µL was added to each well. After incubation for 1 h, the wells were washed 704 and 10  $\mu$ L of ELISA Pico Chemiluminescent Substrate (diluted 1:2 in MilliQ H<sub>2</sub>O) was dispensed into 705 each well. After a 5 min incubation with shaking, plates were read on an Neo2 plate reader (BioTek 706 Instruments) at 20 ms/well and a read height of 1.0 mm.

707

## 708 Colorimetric snELISAs: Toronto protocol and optimization

The snELISA assay was performed as described <sup>13</sup> with the indicated antigens and ACE2. All wash steps 709 710 included four washes in 200 µL PBST. RBD 319–541 or spike was adsorbed onto 96-well high-binding 711 polystyrene Greiner Bio-One plates (Thermo Fisher Scientific, #655061) at 100 or 200 ng/well, 712 respectively, in 50 µL PBS and incubated overnight at 4°C. Plates were washed, then blocked for 1–1.5 713 h at room temperature with 200 µL 3% bovine serum albumin (BSA; BioShop Canada Inc., SKI400.1). 714 After washing, serum or plasma was added to the plate at the indicated concentrations in 50 µL 1% 715 BSA in PBST (final concentration) and incubated for 1 h. Wells were washed and incubated with 50 µL 716 of biotinylated recombinant ACE2 as indicated for 1 h. After washing, wells were incubated with 44 ng

517 Streptavidin-Peroxidase Polymer, Ultrasensitive (Sigma-Aldrich, S2438) for 1 h. The resultant signal 518 was developed and quantified with TMB-ELISA in an identical manner to the colorimetric direct 519 ELISAs. Due to day-to-day variations in signal, all optical density at 450 nm (OD<sub>450</sub>) values were 520 normalized to the OD<sub>450</sub> of the well without serum or antibody for each sample. All values are 521 expressed as ratios.

722

#### 723 Chemiluminescent snELISAs: Toronto protocol

The automated snELISA assay was performed on the same F7 platform as the direct detection ELISA 724 725 with the same washing protocol and incubation temperature. Greiner 384-well Lumitrac 600 plates 726 were coated with RBD 319–541 (34 ng/well) or spike (50 ng/well) following the same protocol as for 727 direct detection. Before each of the next four steps, the plates were washed four times with PBST: 1) 728 the wells were blocked with 80 µL 3% BSA in PBST for 1 h; 2) Plasma or serum sample was dispensed 729 at the indicated dilutions in 10 or 20  $\mu$ L and incubated for 2 h; 3) 10  $\mu$ L of ACE2-BAP (2.08 ng/well in 730 1% BSA in PBST) or ACE2-Rini (17 ng/well in 1% BSA in PBST) was added to each well and the plates 731 were incubated for 1 h; 4) 10 µL of Streptavidin-Peroxidase Polymer, Ultrasensitive (15 ng/well in 1% 732 BSA in PBST) was added to each well and the plates were incubated for 1 h. Addition of ELISA Pico 733 Chemiluminescent Substrate and reading on the EnVision 2105 Multimode Plate Reader (PerkinElmer) 734 were performed as for direct detection. All values were normalized to blanks (with no samples added) 735 on the same 384 well plate.

736

#### 737 Chemiluminescent snELISAs: Ottawa protocol

The surrogate neutralization ELISA first described in <sup>13</sup> was adapted and optimized for compatibility 738 739 with the Hamilton MicroLab STAR robotic liquid handler. The methods for plate washing steps, 740 incubations, and data acquisition were as described for the automated chemiluminescent ELISA. 384-741 well high-binding polystyrene Nunc plates (Thermo Fisher Scientific, #460372) were coated with 100 742 ng/well of spike or RBD 319–541, centrifuged in a plate spinner to ensure even coating, and incubated 743 overnight with rocking at 4°C. Plates were washed, 80 µL of blocking solution (3% w/v skim milk 744 powder in PBST) was added to each well, and the plates were incubated for 1 h at room temperature 745 on a shaker at 700 rpm. During the blocking step, serum/plasma samples or DBS eluates were diluted 746 in skim milk powder in PBST to a final milk concentration of 1% w/v. For single-point neutralizations, 747 samples were diluted 1:5, or to calculate the half maximal effective concentration (EC50), the samples 748 were titrated using a 5-point curve (1:5, 1:25, 1:125, 1:625, 1:6,250). To facilitate quality control, 749 downstream analysis, and cross-plate comparisons, standard curves of NRCoV2-20-Fc and three dilutions (1:5, 1:125, and 1:6,250) of pooled positive and negative serum samples were included in 750 751 auadruplicate on each plate. Serum-free/ACE2-free and serum-free wells were also included on each 752 plate to establish the minimum and maximum signals, respectively. Plates were washed, and samples 753 and controls (20  $\mu$ L) were added to the wells and incubated for 2 h. Plates were then washed, and 6.5 754 ng of ACE2-BAP diluted in 1% w/v skim milk powder in PBST was added to each well and incubated for 755 1 h. Plates were again washed, and Streptavidin-Peroxidase Polymer (Sigma #S2438), diluted in 1% w/v skim milk powder in PBST at a concentration of 1.25 ng  $\mu L^{-1}$  (25 ng/well) was added to each well 756 and incubated for 1 h. Plates were washed a final time and 20 µL of ELISA Pico Chemiluminescent 757 758 Substrate (diluted 1:2 in MilliQ  $H_2$ 0) was dispensed into each well. After a 5-min incubation, plates 759 were read on an Neo2 plate reader (BioTek Instruments) at 20 ms/well and a read height of 1.0 mm. 760 Assay optimization data are presented in Supplementary Figure 14.

- 761
- 762 Data analysis: Toronto

763 Quality control and determination of relative ratios: Raw values for each sample (luminescence 764 counts per second) were normalized to a blank-subtracted reference point from the reference curve  $(0.0156 \ \mu g \ mL^{-1}$  for VHH72-Fc (for spike/RBD) or 0.0625  $\ \mu g \ mL^{-1}$  for anti-N (for N)) to create relative 765 ratios. For each automated test, the raw values and relative ratios of each control were compared to 766 767 those of prior tests to confirm their similarity. The distributions of the raw values of the reference 768 points and positive controls compared to the blanks and the reference points for each antigen 769 compared to each other should be within the 90% confidence ellipse of the distributions of previous 770 tests. In addition, the reference points should be within 15% coefficient of variation (CV) of prior runs. 771 The log<sub>10</sub> sample density distributions of the raw values and relative ratios were compared to prior 772 runs to confirm that they were within range. For points outside of these ranges, the individual control 773 was either removed (e.g. if it was a single outlier out of the four on the plate) or the plate or test was 774 repeated.

775

776 Receiver-operating characteristic (ROC) analysis: Samples acquired prior to November 2019 (pre-COVID) were considered true negatives and samples from convalescent patients with PCR-confirmed 777 778 COVID-19 were considered true positives (for IgM and IgA analyses, we selected positives that were 779 collected 20–40 d post-symptom onset). ROC analysis using relative ratios was performed with the pROC package in R<sup>49</sup> with default parameters. For IgG (serum/plasma and DBS), the analysis was 780 performed in duplicate, with individual replicates considered individual samples. To avoid having 781 782 samples with technical errors skew the threshold determination, negative plasma samples that were 783 positive in only one replicate and negative DBS samples whose values were more than four standard 784 deviations (SDs) from the mean of the log distribution of negative samples were removed from the 785 analysis.

786

Thresholding based on the control mean: For plasma and serum IgG, negative controls (blanks, IgG pools, 0.25 and 0.0625  $\mu$ L/well of a negative master mix (including equal volumes of four pre-COVID-19 samples (N2, N11, N39, N41), *n* = 1,320 for spike, 1,248 each for RBD and N) from 23 experiments over 4 months were included in the analysis. We used three SDs from the mean of the log<sub>10</sub> distribution of the relative ratios of these negative controls as the threshold for each antigen. The same strategy was employed for IgA (72 negative controls from two experiments 1 month apart) and IgM (80 negative controls from three experiments over 2 months).

794

Scoring positives: Positive and negative results were first defined for each antigen, based on the defined thresholds. For projects where an overall assessment of the confidence of antibody detection in a sample is required, we imposed a sample-level rule: the sample must have passed positivity in at least 2 out of 3 antigen tests.

799

800 Other data analyses: Plots were generated in R using the ggplot2, lattice, latticeExtra, grid, and 801 gridExtra packages. Correlations between samples were calculated using the cor() function in the R 802 stats package, using the Spearman method. The density distributions of the log of the signals scaled to 803 the reference were separated using the normalmixEM mixtool function in the R mixtools package, 804 based on an expected minimization of only two subpopulations assumed to have a Gaussian 805 distribution. normalmixEM initialization, mean, and SD parameters were based on visual estimation of 806 the density distribution of the log of the signal scaled to the reference. The initially assumed 807 proportion between the two subpopulations was set to 50%. Density distributions were plotted using

808 default R parameters (bandwidth: bw.nrd0, which implements a rule-of-thumb for choosing the 809 bandwidth of a Gaussian kernel density estimator).

810

811 Calibration to the WHO standard for antibody detection: For each antigen, the relative ratio from the 812 WHO International Standard (IS, National Institute for Biological Standards and Control (NIBSC, South 813 Mimms, United Kingdom), Code 20/136, pooled convalescent plasma) at different sample dilutions (in binding antibody units (BAU) mL<sup>-1</sup>) was represented in log-log scale. The response curve was modelled 814 by an S-shaped sigmoid curve ( $y = a^*x/(1+b^*x)+c$ , expressed in  $\log(y)$ ,  $\log(x)$  coordinates). The nls 815 816 function (nonlinear least squares) from the R stats package was used to best match the response to 817 the measured data. The interval where the log response was considered linear to the log of the BAU mL<sup>-1</sup> was selected visually. The lm (linear model) function from the R stats package was used to obtain 818 819 the parameters of the linear approximation of the curve (Figure 3a). The WHO International 820 Reference panel (NIBSC code 20/268), which contains pooled plasma samples that are Negative (code 821 20/142), Low (code 20/140), Low S High N (code 20/144), Mid (code 20/148), and High (code 20/150), was measured at different concentrations. Estimated BAU mL<sup>-1</sup> values were obtained from the above 822 linear approximation using only sample dilutions that were within this linear range, and further 823 adjusted by accounting for the dilution factor. To convert from relative ratios (RRs) to BAU mL<sup>-1</sup> for 824 825 plasma or serum samples where only the reference curve was included in the same test, (Figure 3d), a 826 conversion formula can be applied:

827

829

828  $\log_2(\text{sample BAU mL}^{-1} \text{ at dilution fold d}) = (\log_2(\text{sample RR}) - a)/b + \log_2(d)$ 

830 where a and b represent the y-intercept and slope of the linear interval of the IS curve 831 (Supplementary table 4).

832

833 <u>Calibration to the WHO standard for snELISA</u>: The WHO IS and the WHO International Reference 834 Panel were analyzed by snELISA at the indicated dilutions to convert values to International Units (IU 835 mL<sup>-1</sup>). The same approach was applied as for the antibody detection ELISA except we used the sample 836 relative ratio (RR) instead of the log<sub>2</sub> of the sample RR because the linear range was larger. We then 837 applied this formula:

838

840

839  $\log_2(\text{sample IU mL}^{-1} \text{ at dilution fold d}) = (\text{sample RR} - a)/b + \log_2(d)$ 

841 where a and b represent the y-intercept and slope of the linear interval of the IS curve respectively 842 and d is the dilution factor of the sample. For RBD as antigen, a = 1.58 and b = -0.16.

- 843
- 844 Data analysis: Ottawa

845 For consistency in data processing, a constant plate layout was established, containing all controls and 846 standard curves in quadruplicate (Supplementary figure 11a). Luminescence values obtained from the 847 isotype- and antigen-specific standard curve were modeled using a four-parameter log-logistic 848 function to identify the inflection point (Supplementary figure 11b). Blank-subtracted luminescence 849 values were scaled in relation to the curve to allow data normalization for subsequent processing. 850 Using a 3% false discovery rate (FDR) calculated using a density distribution from a screen of adult and 851 pediatric pre-pandemic samples, a threshold was established for each isotype-antigen combination. 852 Signal to threshold (also known as signal-to-cutoff, S/CO) ratios specific to each isotype-antigen combination were then calculated and sample positivity was determined (Supplementary figure 11c-853

d). For example, for IgG, both spike and N antigens were considered. If respective antigens were detected over the established threshold (S/CO  $\ge$  1), a positive call was made. All analyses were performed in R. Density distributions were determined using the default density function with default parameters. Standard curve processing was performed using the LL.4 four-parameter log-logistic selfstarter function from the drc package <sup>50</sup>, also with default parameters. Plots were generated using the ggplot2 and reshape2 packages.

860

Using NML panel 4, containing known positive and negative DBS samples, the optimal FDR threshold value for SARS-CoV-2 IgG-positive calls was determined by testing FDRs of 1–100% and calculating the number of true positive (TP), false positive (FP), true negative (TN), and false negative (FN) samples. Maximum accuracy occurred at an FDR of 3% (Supplementary figure 11e). ROC curves and associated area under the curve measurements were generated in R using the pROC package with default parameters (Table 2, Supplementary figure 11f–h).

867

To convert luminescence values into BAU ml<sup>-1</sup>, the WHO IS was titrated for spike, RBD, and N (Supplementary figure 9). Scaled luminescence was calculated, as above, and response curves were modelled using the LL.4 four-parameter log-logistic self-starter function from the drc package with default parameters. The interval where the scaled luminescence response curves were considered linear to BAU was selected visually. Calibration of the three antigens was performed using the NIBSC 20/268 reference panel. The following formula was used to convert scaled luminescence values to BAU mL<sup>-1</sup>:

- 875
- 876 BAU ml<sup>-1</sup> =  $e^{((\ln(((Upper-Lower)/(ScaledLuminescence-Lower)) 1))/(Slope + \ln(EC50))} *$  dilution factor
- 877

For snELISA, the WHO IS was titrated and ACE2-spike binding inhibition was reported as a function of IUs. Blank adjusted luminescence values were converted to inhibition of ACE2-spike binding; maximal signal (i.e. 0% inhibition) was measured in absence of convalescent plasma (1% w/v skim milk powder in PBST ). The normalized data was fitted using the LL.4 four-parameter log-logistic self-starter function from the drc package with default parameters in R to correlate binding inhibition to IUs. The following formula was used to convert binding inhibition % to IU ml<sup>-1</sup>:

884

885  $|U m|^{-1} = e^{((\ln((Upper-Lower)/(\%inhibition-Lower)) - 1))/Slope + \ln(EC50))} * dilution factor$ 

886

# 887 Reagent access

The reagents produced by the NRC and qualified as reference materials (spike [SMT1-1], N [NCAP-1]
 and hACE2-BAP) are available through the Metrology Research Centre Virtual Store (<u>Virtual Store -</u>
 <u>National Research Council Canada: Products in Category Proteins (nrc-cnrc.gc.ca)</u>). A limited panel of
 matched plasma and DBS is available upon request

- 892
- 893 Code availability
- 894 Code is available upon request.
- 895

## 896ACKNOWLEDGMENTS

We thank Alex Pelletier, Denis L'Abbé, Mélanie Duchesne, Simon Lord-Dufour, Manon Ouimet, Brian
Cass, Louis Bisson, Alina Burlacu, Jean-Sébastien Maltais, Sergio Alpuche-Lazcano and other members

899 of the NRC-HHT Mammalian Cell Expression Section for their contribution to the cloning, expression

900 and purification of the various recombinant proteins used in this study. The contribution of Joline 901 Cormier to recombinant protein sample management is greatly appreciated. We are grateful to Joe 902 Schrag, Roger Maurice, and Mathieu Coutu from NRC-HHT (Montreal) for SEC-UPLC and SEC-HPLC 903 analyses. We thank Jamshid Tanha and Martin Rossotti from NRC-HHT (Ottawa) for providing 904 NRCoV2-04-hFc1X7 and NRCoV2-20-hFc1X7 antibodies. We thank Frank Sicheri and Derek Ceccarelli 905 (LTRI) for contributing bacterially expressed N and James Rini (University of Toronto) for contributing 906 RBD and biotinylated ACE2 protein to compare with the reagents described here. We also thank 907 Lauren Caldwell for preprocessing some of the data generated from automated ELISAs. We thank 908 Bruce Mazer, Mel Krajden and members of the COVID-19 Immunity Task Force (CITF) for coordinating 909 immune response studies across the country and for supporting assay development and 910 implementation. This is NRC's publication #NRC-HHT 53561A. We acknowledge support from Ontario 911 Together and funding from the Canadian Institutes of Health Research (CIHR; #VR1-172711, GA1-912 177703 and #439999) and the COVID-19 Immunity Task Force (CITF). We also acknowledge financial 913 support from the NRC's Pandemic Response Challenge Program. Funding for initial assay development 914 in the Gingras lab was provided through generous donations from the Royal Bank of Canada and the 915 Krembil Foundation to the Sinai Health System Foundation. The robotics equipment used is housed in 916 the Network Biology Collaborative Centre at the LTRI, a facility supported by the Canada Foundation 917 for Innovation, the Ontario Government, and Genome Canada and Ontario Genomics (OGI-139). 918 Assay development in the Langlois lab and the purchase of robotic equipment was supported by a 919 grant from the CIHR (#VR2-172722 and VS2 - 175569) and supplemental funding from the CITF. Kento 920 T Abe was a recipient of an Ontario Graduate Scholarship and is supported by a CIHR CGS-D 921 studentship. Yannick Galipeau is supported by a CIHR CGS-M studentship. Mariam Maltseva holds a 922 Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST). Anne-Claude Gingras 923 is the Canada Research Chair in Functional Proteomics, and Marc-André Langlois, Anne-Claude 924 Gingras, Jeffrey Wrana, and Samira Mubareka are members of CoVaRR-Net, the CIHR Coronavirus 925 Variants Rapid Response Network.

926

928

927 **Competing interests:** The authors declare no competing interests for this manuscript.

929 Contributors: Karen Colwill, Anne-Claude Gingras, Marc-André Langlois, and Yves Durocher conceived 930 the study. Karen Colwill, Anne-Claude Gingras, Marc-André Langlois, Matthew Stuible, Christian 931 Gervais, Yannick Galipeau, Corey Arnold, and Yves Durocher wrote the paper. Yves Durocher, 932 Matthew Stuible and Christian Gervais designed, performed, and validated reagent purification 933 procedures. Linda Bennett, Kevin Yau, Angel X Li, Aimee Paterson, Michelle A Hladunewich, Pamela J 934 Goodwin, Samira Mubareka, Allison J McGeer and Steven J Drews contributed essential patient 935 samples. Bhavisha Rathod was responsible for sample intake at the Toronto site. François Cholette, 936 Christine Mesa prepared and helped evaluate DBS panels and John Kim supervised the DBS panel 937 evaluation. Yannick Galipeau, Corey Arnold, Bhavisha Rathod, Jenny H Wang, Mariam Maltseva, 938 Mariam Iskilova, and Mahya Fazel-Zarandi performed serology experiments. Karen Colwill, Miriam 939 Barrios-Rodiles, Kento T Abe, Martin Pelchat, Lynda Rocheleau, Yannick Galipeau and Adrian 940 Pasculescu performed data analysis. Martin Pelchat and Adrian Pasculescu performed statistical 941 modelling. Karen Colwill, Kento T Abe, Adrian Pasculescu, Yannick Galipeau, Mariam Maltseva, Lynda 942 Rocheleau, Matthew Stuible and Martin Pelchat generated figures for the paper. Miriam Barrios-943 Rodiles and Jeffrey L Wrana provided oversight of the Toronto screening facility.

All the authors gave final approval of the version to be published and agreed to be accountable for all
 aspects of the work. Marc-André Langlois, Anne-Claude Gingras, and Yves Durocher are co-senior
 corresponding authors.

947

948 **Data Sharing:** Raw and normalized values from the automated assays are provided in Supplementary 949 table 5. R scripts used to analyze the data are available upon request.

- 950
- 951
- 952

## 953 **References**

- 9541.Johns Hopkins University COVID-19 Dashboard. [cited February 25 2021]. Available from:955https://coronavirus.jhu.edu/map.html.
- 9562.Few Canadians had antibodies against SARS-CoV-2 in early 2021 Statistics Canada. [updated957July 6 2021; cited February 25 2022]. Available from: <a href="https://www150.statcan.gc.ca/n1/daily-guotidien/210706/dq210706a-eng.htm">https://www150.statcan.gc.ca/n1/daily-</a>958quotidien/210706/dq210706a-eng.htm.
- 9593.Serotracker. [updated February 22 2022; cited February 25 2022]. Available from:960https://serotracker.com/en/Explore.
- 961 4. Chung H, He S, Nasreen S, *et al.* Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines
  962 against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada:
  963 test negative design study. *BMJ* 2021; **374**: n1943.
- 9645.Health Infobase Canada -COVID-19 Vaccination Coverage. [updated February 18 2022; cited965February 25 2022]. Available from: <a href="https://health-infobase.canada.ca/covid-19/vaccination-</a>966coverage/.
- 967 6. Van Caeseele P, Canadian Public Health Laboratory N, Bailey D, et al. SARS-CoV-2 (COVID-19)
  968 serology: implications for clinical practice, laboratory medicine and public health. *Cmaj* 2020;
  969 **192**: E973-E979.
- 9707.Favresse J, Eucher C, Elsen M, et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the971Analytical Kit: A Report for Up to 10 Months after Infection. Microorganisms 2021; 9.
- 9728.Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-9732 spike antigens in COVID-19 patients. Science immunology 2020; 5.
- 9749.Sherina N, Piralla A, Du L, et al. Persistence of SARS-CoV-2-specific B and T cell responses in975convalescent COVID-19 patients 6-8 months after the infection. Med (N Y) 2021; 2: 281-295976e284.
- 97710.Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8978months after infection. Science (New York, NY 2021; 371.
- 97911.Gallais F, Gantner P, Bruel T, et al. Evolution of antibody responses up to 13 months after980SARS-CoV-2 infection and risk of reinfection. EBioMedicine 2021; 71: 103561.
- 981 12. Feng C, Shi J, Fan Q, *et al.* Protective humoral and cellular immune responses to SARS-CoV-2
  982 persist up to 1 year after recovery. *Nat Commun* 2021; **12**: 4984.
- 98313.Abe KT, Li Z, Samson R, et al. A simple protein-based surrogate neutralization assay for SARS-984CoV-2. JCI Insight 2020; 5.
- Mattiuzo G, Bentley E, Hassall M, *et al.* Establishment of the WHO International Standard and
  Reference Panel for anti-SARS-CoV-2 antibody. WHO Expert Committe on Biological
  Standardization. WHO/BS/2020.2403. In: Organization WH, editor. 2020.

988 15. Stuible M, Gervais C, Lord-Dufour S, et al. Rapid, high-yield production of full-length SARS-CoV-989 2 spike ectodomain by transient gene expression in CHO cells. J Biotechnol 2021; **326**: 21-27. 990 Ye Q, West AMV, Silletti S, Corbett KD. Architecture and self-assembly of the SARS-CoV-2 16. 991 nucleocapsid protein. Protein Sci 2020; 29: 1890-1901. 992 Wrapp D, De Vlieger D, Corbett KS, et al. Structural Basis for Potent Neutralization of 17. 993 Betacoronaviruses by Single-Domain Camelid Antibodies. Cell 2020; 181: 1436-1441. 994 Morley GL, Taylor S, Jossi S, et al. Sensitive Detection of SARS-CoV-2-Specific Antibodies in 18. 995 Dried Blood Spot Samples. Emerg Infect Dis 2020; 26: 2970-2973. 996 Biosafety advisory: SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2) -19. 997 Government of Canada. [updated November 23 2021; cited February 25 2022]. Available from: 998 https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/biosafety-999 directives-advisories-notifications/novel-coronavirus-january-27.html. 1000 Galipeau Y, Siragam V, Laroche G, et al. Relative Ratios of Human Seasonal Coronavirus 20. 1001 Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2. 1002 EBioMedicine 2021; 74: 103700. 1003 Yau K, Abe KT, Naimark D, et al. Evaluation of the SARS-CoV-2 Antibody Response to the 21. 1004 BNT162b2 Vaccine in Patients Undergoing Hemodialysis. JAMA Netw Open 2021; 4: e2123622. 1005 Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and 22. asymptomatic SARS-CoV-2 infection. Nature medicine 2021; 27: 2032-2040. 1006 1007 Approved COVID-19 Vaccines - Goverment of Canada, Jupdated February 24 2022; cited 23. 1008 February 25 2022]. Available from: https://www.canada.ca/en/health-canada/services/drugshealth-products/covid19-industry/drugs-vaccines-treatments/vaccines.html. 1009 1010 24. Approved COVID-19 Vaccines - US Food and Drug Administration. [updated February 11 2022; 1011 cited February 25 2022]. Available from: https://www.fda.gov/emergency-preparedness-and-1012 response/coronavirus-disease-2019-covid-19/covid-19-vaccines. COVID-19 approved vaccines - European Medicines Agency. [cited February 25 2022]. 1013 25. 1014 Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-1015 threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines. 1016 26. Duarte N, Yanes-Lane M, Arora RK, et al. Adapting Serosurveys for the SARS-CoV-2 Vaccine 1017 Era. Open Forum Infect Dis 2022; 9: ofab632. 1018 Lv H, Wu NC, Tsang OT, et al. Cross-reactive Antibody Response between SARS-CoV-2 and 27. 1019 SARS-CoV Infections. Cell Rep 2020; 31: 107725. 1020 28. Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and 1021 its immune cross-reactivity with SARS-CoV. Nat Commun 2020; 11: 1620. 1022 Dobano C, Santano R, Jimenez A, et al. Immunogenicity and crossreactivity of antibodies to the 29. 1023 nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity 1024 studies. Transl Res 2021; 232: 60-74. 1025 Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and 30. 1026 protection from disease in a small animal model. Science (New York, NY 2020; 369: 956-963. 1027 Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike 31. 1028 protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. 1029 Science immunology 2020; 5. 1030 Science Brief: Omicron (B.1.1.529) Variant. [updated December 2 2021; cited February 25 32. 1031 2022]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-1032 briefs/scientific-brief-omicron-variant.html.

1033 33. Tuite AR, Fisman D, Abe KT, et al. Estimating SARS-CoV-2 Seroprevalence in Canadian Blood 1034 Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays. *Microbiol Spectr* 1035 2022; 10: e0256321. 1036 34. Saeed S, O'Brien SF, Abe K, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-1037 2) seroprevalence: Navigating the absence of a gold standard. *PloS one* 2021; 16: e0257743. 1038 Tang X, Sharma A, Pasic M, et al. Assessment of SARS-CoV-2 Seropositivity During the First and 35. 1039 Second Viral Waves in 2020 and 2021 Among Canadian Adults. JAMA Netw Open 2022; 5: 1040 e2146798. 1041 CanPath National Study. [updated June 23 2021; cited February 25 2022]. Available from: 36. 1042 https://canpath.ca/2021/06/early-results-from-canpaths-national-study-confirm-antibody-1043 levels-are-stronger-after-receiving-two-doses-of-covid-19-vaccine. 1044 37. Walmsley S, Szadkowski L, Wouters B, et al. Safety and Efficacy of Preventative COVID 1045 Vaccines: The StopCoV Study. medRxiv 2022: 2022.2002.2009.22270734. 1046 Dayam RM, Law JC, Goetgebuer RL, et al. Antibody and T cell responses to SARS-CoV-2 mRNA 38. 1047 vaccines during maintenance therapy for immune-mediated inflammatory diseases. medRxiv 1048 2022: 2022.2001.2026.22269856. 1049 39. Yau K, Chan CT, Abe KT, et al. Diferences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-1050 BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. *Cmaj* 1051 2022. 1052 40. Abe KT, Hu Q, Mozafarihashjin M, et al. Neutralizing antibody responses to SARS-CoV-2 1053 variants in vaccinated Ontario long-term care home residents and workers. medRxiv Preprint 1054 2021: 2021.2008.2006.21261721. 1055 41. Vinh DC, Gouin J-P, Cruz-Santiago D, et al. Real-world serologic responses to Extended-interval 1056 and Heterologous COVID-19 mRNA vaccination in Frail Elderly - Interim report from a prospective observational cohort study. medRxiv Preprint 2021: 2021.2009.2016.21263704. 1057 CITF Funded Projects. [cited February 24 2022]. Available from: 1058 42. 1059 https://www.covid19immunitytaskforce.ca/task-forceresearch/#:~:text=Our%20Funded%20Research,Cutting%20Themes%2C%20and%20Immunity 1060 1061 %20Modelling. 1062 43. Shi C, Shin YO, Hanson J, Cass B, Loewen MC, Durocher Y. Purification and characterization of a recombinant G-protein-coupled receptor, Saccharomyces cerevisiae Ste2p, transiently 1063 1064 expressed in HEK293 EBNA1 cells. *Biochemistry* 2005; 44: 15705-15714. 1065 44. Dorion-Thibaudeau J, St-Laurent G, Raymond C, De Crescenzo G, Durocher Y. Biotinylation of 1066 the Fcgamma receptor ectodomains by mammalian cell co-transfection: application to the development of a surface plasmon resonance-based assay. J Mol Recognit 2016: 29: 60-69. 1067 1068 45. Darnell ME, Taylor DR. Evaluation of inactivation methods for severe acute respiratory 1069 syndrome coronavirus in noncellular blood products. Transfusion 2006; 46: 1770-1777. 1070 Cholette F, Mesa C, Harris A, et al. Dried blood spot specimens for SARS-CoV-2 antibody 46. testing: A multi-site, multi-assay comparison. PloS one 2021; 16: e0261003. 1071 1072 Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 47. 1073 seroconversion in humans. Nature medicine 2020; 26: 1033-1036. 1074 48. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 1075 seroconversion in humans. Nature medicine 2020. 1076 49. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC bioinformatics 2011; 12: 77. 1077

- 107850.Ritz C, Baty F, Streibig JC, Gerhard D. Dose-Response Analysis Using R. PloS one 2015; 10:1079e0146021.
- 1080

## 1081 Figure Legends

1082

**Figure 1.** High-quality reagents for SARS-CoV-2 serology. **(a)** Reagents comprising the protein toolbox (left panel) are used in high-throughput plate-based ELISAs for antibody detection and surrogate neutralization (right panel). **(b)** The reagents were analyzed on Coomassie-stained polyacrylamide gels under reducing conditions to assess their purity. Molecular weight markers (kDa) are shown to the left of the gels.

1088

1098

1089 Figure 2. Development of high-throughput ELISAs for plasma or serum. (a) Known negative (pre-1090 COVID-19) and positive (confirmed convalescent) samples (0.0625  $\mu$ L/well) were tested in an 1091 automated antibody detection ELISA in two separate replicates 7 weeks apart. Spearman correlations 1092 are noted. (b) Density distributions of negative samples were plotted for each antigen. The black lines 1093 represent the mean of the negative distribution (dotted) and three SDs from the mean (solid; the 1094 relative ratio is indicated). The blue line represents the thresholds established by ROC analysis. (c) 1095 Comparison of the antigens with a set of known negative and positive samples at 0.0625  $\mu$ L/well. 1096 Spearman correlations are shown. For both (a) and (c), dashed lines represent the thresholds as 1097 defined by the 3-SD negative distribution shown in (b) and listed in Table 1.

1099 Figure 3. Conversion of Ottawa and Toronto ELISA data to WHO BAUs and comparison to the WHO 1100 Reference Panel 20/268. (a) The 20/268 reference panel at the indicated dilutions (arrows) was fitted 1101 onto a dose-response curve of the IS with the measured values expressed as relative ratios (Toronto). 1102 A 1:160 dilution (0.0625 µL/well) of sample was used except when it was out of the linear range of the 1103 fitted line in which case the 1:2560 dilution (0.0039  $\mu$ L/well) was used. (b) IgG levels in the five 1104 samples in the 20/268 reference panel are represented for spike, its RBD, and N (n = 12, 4 replicates 1105 at 1:500, 1:1,000, 1:2,500 dilutions). (c) Box plots for Ottawa (orange) show the median of the 12 1106 samples from B. Box plots for Toronto (blue) show the median of individual measurements (n = 4) for 1107 the selected dilution (1:2560 (0.0039  $\mu$ L/well) for Mid and High for spike and N, High for RBD, the rest 1108 were at 1:160 (0.0625  $\mu$ L/well)). The WHO bar graph shows the geometric mean from the WHO study 1109 and the lines with half arrows represent a 0.5-2-fold range from the geometric mean. (d) Reference 1110 curves (VHH72-Fc for spike/RBD, anti-N for N) were plotted for each antigen either from the same tests in which the IS was analyzed or from 25 different tests over 3 months (shown as faded black 1111 lines with a thicker median line in black). The blue dashed lines represent the limits of the linear 1112 intervals for the curves and the pink arrows represent the BAU mL<sup>-1</sup> at those points. As the reference 1113 curves are parallel to the IS within the linear interval, a conversion factor can be applied to convert 1114 relative ratios to international BAU mL<sup>-1</sup> units (Supplementary table 4). For illustrations purposes to 1115 show IS and reference curves in the same panel, the X-axis is BAU mL<sup>-1</sup> for IS and  $\mu$ g mL<sup>-1</sup> \* 100 for the 1116 1117 reference curves.

1118

Figure 4. Dose response curves or single-point snELISA and conversion to International Units using the Who International Standard. (a) Correlation of spike to RBD as snELISA antigens is shown for 11 samples in a 10-point dilution series (individual curves are shown in Supplementary figure 13). (b) Dose response curves (n = 4) for the spike snELISA. Samples were from convalescent SARS-CoV-2

individuals 3 weeks after 1 or 2 doses of Comirnaty vaccine (Pfizer) or an uninfected individual (from a 1123 1124 surveillance study) 3 weeks post-first dose of Comirnaty. Pooled sera were from 100 individuals with 1125 or without prior SARS-CoV-2 infection. (c) Single point measurements (at 1:5 dilution) using the spike snELISA. (d) Titration of the neutralizing activity of the WHO IS using snELISA. Raw luminescence 1126 1127 values were converted to inhibition of ACE2-Spike binding; maximal signal (i.e. 0% inhibition) was 1128 measured in absence of convalescent plasma (PBS only). The normalized data was fitted with a four-1129 parameter logistic function and the 95% confidence interval (IC95) and two standard deviations (2SD) 1130 is shown. (e) Box plots for the WHO reference panel 20/268 using RBD (blue, Toronto, ACE2 source: 1131 Rini) or spike (orange, Ottawa) as antigens. For RBD, n = 3 at 1:10 dilution for Low, n = 4 at 1:10 dilution for Mid, n = 7 at 1:40 and 1:160 for High. For spike, n = 12 for High (4 replicates at 3 1132 1133 dilutions), n = 8 for LowS HighN and Mid (4 replicates at 2 dilutions) and n = 4 for Low (2 replicates at 1134 2 dilutions). The WHO bar graph shows the geometric mean from the WHO study and the lines with 1135 half arrows represent a 0.5–2-fold range from the geometric mean. No inhibition was seen for the 1136 LowS HighN sample for RBD.

1137

**Figure 5.** Visualization of Data from 3 Antigen testing. The results from the three antigens with known negative and positive samples (a) and samples from a longitudinal study of patients on dialysis at baseline and after their first vaccine dose (b). The dashed lines represent the thresholds for spike and N. The area with positives for both spike and N (colored in gray) is indicative of natural infection and the area showing samples that are N-negative but spike-positive (and RBD-positive if colored) is highlighted in green on the right panel and is indicative of vaccination.

1144

# 

#### **Table 1.** ELISA performance statistics for plasma or serum IgG (Toronto)

	spike	RBD	Ň	$\geq$ 2 positive antigens		
<b>ROC</b> analysis			,	, ,		
AUC	0.978	0.974	0.964	n/a		
Threshold (Cut	0.195	0.073	0.349	n/a		
Point)						
FPR	0.009	0.009	0.009	0.000		
TPR	0.944	0.921	0.811	0.931		
3 SDs from the mean of the negative controls						
Threshold	0.190	0.186	0.396	n/a		
FPR	0.011	0.000	0.007	0.000		
TPR	0.944	0.890	0.786	0.912		
Samples used to assess performance <sup>†</sup>						
Sample cohort	Replicates	Number	Total			
Patients with	1	211	392			
COVID-19	2	181				
Pre-COVID-19	1	300 for N and	560			
(negative)		spike, 296 for				
		RBD				
	2	260 for N and				
		RBD, 258 for				
		spike				

<sup>†</sup>Negative samples were excluded from the analysis for spike and RBD if one replicate was positive.

Antigen	spike	RBD	Ν	$\geq$ 2 positive antigens
AUC	0.991	0.996	0.992	N/A
Threshold (Cut	1.410	0.868	1.171	N/A
Point)				
FPR	0.02	0.01	0.06	0.02
TPR	1.00	1.00	1.00	0.98
Number of samples us	ed to generate RO	C curves <sup>†</sup>		
Antigen	spike	RBD	Ν	$\geq$ 2 positive antigens
Patients with COVID-19	97	97	97	97
Number excluded	2	2	2	2
Total analyzed	95	95	95	95
Pre-COVID-19	90	90	90	90
(negative)				
Number excluded	0	0	0	(

## 1151 **Table 2.** ROC statistics for the DBS IgG ELISA (Ottawa)

<sup>†</sup>NML panel 4. Each sample was analyzed once, and thresholds were defined at 3% FDR as described

in Supplementary figure 11. Two positive samples were excluded as they were early on in infection.

1154

Antigen	spike	RBD	Ν	≥ 2 positive antigens
AUC	0.99	0.99	0.99	N/A
Threshold (Cut point)	0.482	0.324	0.642	N/A
FPR	0.01	0.01	0.01	0.00
TPR	0.98	0.98	0.92	0.98
Number of samples us	ed to generate RO	C curves <sup>†</sup>		
Antigen	spike	RBD	Ν	$\geq$ 2 positive antigens
Patients with COVID-19	97	97	97	97
Number excluded	0	0	0	0
Total analyzed	97	97	97	97
Pre-COVID-19	90	90	90	90
(negative)				
	3	1	2	4

1156 **Table 3.** ROC statistics for the DBS IgG ELISA (Toronto)

<sup>†</sup>NML panel 4. Each sample was analyzed in duplicate (the unique numbers of samples are shown).

1158 Replicates were treated as separate samples in the ROC analysis. Negative samples were excluded

1159 from the analysis if the replicates were > 4 SDs from the mean.

# 1161 Supplementary figures


1162


1163 Supplementary figure 1 – Chromatogram traces for the purified ELISA antigens and detection 1164 reagents.


- 1165 Supplementary figure 2 Purification of recombinant anti-spike antibodies.
- 1166Supplementary figure 3 Titration curves of 32 serum samples from CBS using automated ELISAs to1167detect (a) spike, (b) RBD 331–521, and (c) N antibodies.
- 1168 Supplementary figure 4 Performance of the IgG chemiluminescent ELISAs with plasma and serum.
- 1169Supplementary figure 5 Comparison between o-Phenylenediamine dihydrochloride (OPD) and11703,32,5,52-tetramethylbenzidine (TMB) as colorimetric substrates for the1171manual 96-well plate ELISA.
- 1172Supplementary figure 6 Comparison of IgG-HRP secondary antibody performance (a) Analysis of NRC1173IgG-HRP secondary (detection) antibodies.
- 1174 Supplementary figure 7 Elution and secondary antibody optimizations for IgG ELISAs using DBSs.
- 1175 Supplementary figure 8 IgA and IgM ELISAs.
- 1176Supplementary figure 9 Conversion of serology data to WHO BAUs and validation of SARS-CoV-21177IgG profiling performed on the uOttawa automated serology platform.
- 1178 Supplementary figure 10 DBS optimization.
- 1179 Supplementary figure 11 Processing and validation of the Ottawa automated serology platform.
- 1180 Supplementary figure 12 ROC curve for panel 4 DBS IgG analysis.
- 1181 Supplementary figure 13 Optimization and testing of NRC reagents for snELISA.
- 1182 Supplementary figure 14 Optimization of the snELISA for the automated platform.
- 1183 Supplementary figure 15 Optimized snELISA for the automated platform.
- 1184 Supplementary figure 16 Optimization of the NRC reagents.
- 1185Supplementary figure 17 Optimization of IgG#5-HRP and recombinant antibodies for1186chemiluminescent assays
- 1187
- 1188

# 1189 Supplementary Tables

- 1190
- 1191 Supplementary table 1 Reagent information.
- 1192 Supplementary table 2 Comparison of manual and automated ELISAs.
- 1193 Supplementary table 3 ELISA performance statistics for plasma or serum IgA and IgM (Toronto).
- 1194 Supplementary table 4 –Conversion of relative ratios to international units (BAU mL<sup>-1</sup>) for plasma or 1195 serum.
- 1196 Supplementary table 5 Raw data from automated experiments.
- 1197







Colwill et al. Figure 3

